Indeed, SKO-001 significantly restored HFD-induced ectopic lipid accumulation in the liver, along with reduced mRNA expression of SREBP-1c, C/EBPα, and PPARγ. Additionally, SKO-001 reduced the mRNA levels of two important fibrosis markers, α-SMA and Col1α1, along with αSMA protein levels, as determined by α-SMA immunostaining, suggesting that SKO-001 may also be applicable to hepatic fibrosis and cirrhosis. Here, CEBPA is linked to Cirrhosis.